Real-world data for the use of emicizumab in haemophilia A patients with inhibitors - First nationwide report from Korea

被引：6

作者：

Hahn, Seung Min ^{[1
,2
]}

Han, Jung Woo ^{[1
,2
]}

Kim, Jin Seok ^{[3
]}

Shim, Ye Jee ^{[4
]}

Kim, Soyon ^{[5
]}

Kim, Hugh Chul ^{[5
]}

Park, Young Shil ^{[6
]}

Lyu, Chuhl Joo ^{[1
,2
,7
]}

机构：

[1] Yonsei Univ, Coll Med, Dept Pediat, Seoul, South Korea

[2] Yonsei Univ, Severance Hosp, Yonsei Canc Ctr, Dept Pediat Hematol Oncol,Coll Med, Seoul, South Korea

[3] Yonsei Univ, Dept Internal Med, Coll Med, Seoul, South Korea

[4] Keimyung Univ, Dongsan Hosp, Dept Pediat, Sch Med, Daegu, South Korea

[5] Kim & Lees Internal Med Clin, Seoul, South Korea

[6] Kyung Hee Univ, Kyung Hee Univ Hosp Gangdong, Dept Pediat, Coll Med, Seoul, South Korea

[7] Yonsei Univ, Severance Hosp, Coll Med, Yonsei Canc Ctr,Dept Pediat Hematol Oncol, 50-1 Yonseiro, Seoul 03722, South Korea

来源：

HAEMOPHILIA | 2023年 / 29卷 / 04期

关键词：

PROPHYLAXIS;

D O I：

10.1111/hae.14819

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1163 / 1166

页数：4

共 50 条

[31] Patients with haemophilia A with inhibitors in China: a national real-world analysis and follow-up
Dou, Xueqing
Liu, Wei
Poon, Man-Chiu
Zhang, Xinsheng
Wu, Jingsheng
Zeng, Xiaojing
Wu, Runhui
Hu, Qun
Li, Chengping
Wang, Xiaomin
Song, Xuewen
Chen, Lingling
Zhang, Lei
Xue, Feng
Yang, Renchi
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 192 (05) : 900 - 908
[32] Efficacy, safety and cost of emicizumab prophylaxis in haemophilia A patients with inhibitors: A nationwide observational study in Taiwan
Shen, Ming-Ching
Chou, Sheng-Chieh
Chiou, Shyh-Shin
Lin, Pei-Chin
Chen, Yeu-Chin
Lin, Hsuan-Yu
Lee, Yang-Cheng
Huang, Cih-En
Weng, Te-Fu
Huang, Ting-Huan
Chung, Chih-Yuan
Chen, Jiann-Shiuh
Chen, Shu-Huey
Cheng, Shin-Nan
Hsiao, Chih-Cheng
Huang, Yen-Min
Chen, Shih-Hsiang
Yu, Yuan-Bin
Lin, Shih-Chiang
Lin, Ching-Yeh
Peng, Ching-Tien
Wang, Jiaan-Der
HAEMOPHILIA, 2023, 29 (06) : 1499 - 1508
[33] Efficacy of Galcanezumab for the treatment of migraine in Korea: the first real-world data from an Asian country
Kwon, S.
Gil, Y. E.
Lee, M. J.
JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 52 - 52
[34] Real-World Safety of Emicizumab: Interim Analysis of the European Haemophilia Safety Surveillance (EUHASS) Database
Nissen, Francis
Jiang, Yanrong
Hiew, Hwai Jing
Aizenas, Martynas
Tobaruela, Guillermo
Jew, Lyle
BLOOD, 2022, 140
[35] Efficacy of Galcanezumab for the treatment of migraine in Korea: the first real-world data from an Asian country
Kwon, S.
Gil, Y. E.
Lee, M. J.
CEPHALALGIA, 2021, 41 (1_SUPPL) : 78 - 79
[36] Real-World Experience with Emicizumab for Hemophilia a from the Physician Perspective Based on Survey Data
Recht, Michael
Salehi, Hanna
Blazos, Chris
Lai, Sophie
Morton, Ella
Lee, Lucy
Biondo, Juliana M. L.
Lee, Janet S.
BLOOD, 2024, 144 : 5078 - 5079
[37] A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors
Escobar, Miguel
Bullano, Michael
Mokdad, Ali G.
Caicedo, Jorge
Schultz, Bob G.
Fan, Qi
Verma, Sumit
EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (06) : 467 - 474
[38] Use of global assays to monitor emicizumab prophylactic therapy in patients with haemophilia A with inhibitors
Brophy, Donald F.
Martin, Erika J.
Kuhn, Janice
HAEMOPHILIA, 2019, 25 (02) : E121 - E123
[39] BURDEN OF ILLNESS OF HAEMOPHILIA A PATIENTS USING DATA FROM CHESS II, A EUROPEAN REAL-WORLD DATA STUDY
Young, L.
Loftus, J.
Chen, Y.
Alvir, J.
Chi, L.
King, A.
Winburn, I.
HAEMOPHILIA, 2020, 26 : 95 - 95
[40] Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea
Lee, Hankil
Cho, Hyeonseok
Han, Jung Woo
Kim, Ah-Young
Park, Seonyoung
Lee, Minjun
Cho, Sunghwa
Baik, Deborah
Kang, Hye-Young
HAEMOPHILIA, 2021, 27 (01) : E12 - E21

← 1 2 3 4 5 →